Stocktoria

QIAGEN N.V. QGEN

NYSE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-09-01 · LEI

QIAGEN N.V. financials (annual)

Revenue
$1.34B $1.42B $1.50B $1.53B $1.87B $2.25B $2.14B $1.97B $1.98B $2.09B 2016201720182019202020212022202320242025
Net income
$80.4M $40.4M $190.4M -$41.5M $359.2M $512.6M $423.2M $341.3M $83.6M $424.9M 2016201720182019202020212022202320242025
Free cash flow
$267.1M $196.7M $249.7M $212.9M $325.0M $449.1M $586.0M $309.7M $506.4M $453.3M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.1B$2.0B$2.0B$2.1B$2.3B$1.9B$1.5B$1.5B$1.4B$1.3B
Gross profit$1.3B$967.4M$1.2B$1.4B$1.5B$1.2B$1.0B$1.0B$922.6M$844.7M
Operating income$465.9M$97.7M$409.9M$531.5M$630.1M$386.4M-$26.1M$266.6M$153.4M$98.8M
Interest expense$53.4M$58.4M$54.5M$71.3M$74.2M$67.3M$49.7M$39.0M
Income tax$65.4M$37.6M$88.5M$89.4M$113.2M$80.3M-$36.3M$35.4M$74.0M-$23.4M
Net income$424.9M$83.6M$341.3M$423.2M$512.6M$359.2M-$41.5M$190.4M$40.4M$80.4M
EPS (diluted)$1.94$0.37$1.48$1.84$2.21$1.53$-0.18$0.82$0.17$0.34
Operating cash flow$654.3M$673.6M$459.5M$715.3M$639.0M$457.8M$330.8M$359.5M$286.8M$341.6M
Free cash flow$453.3M$506.4M$309.7M$586.0M$449.1M$325.0M$212.9M$249.7M$196.7M$267.1M
Cash & equivalents$839.0M$663.6M$668.1M$730.7M$880.5M$598.0M$623.6M$1.2B$657.7M$439.2M
Inventory$301.9M$279.3M$398.4M$358.0M$327.5M$291.2M$170.7M$162.9M$155.9M$136.6M
Total assets$6.3B$5.7B$6.1B$6.3B$6.1B$5.9B$5.2B$5.7B$5.0B$4.3B
Shareholders' equity$3.8B$3.6B$3.8B$3.5B$3.1B$2.8B$2.5B$2.6B$2.5B$2.6B

Growth · year-over-year · Revenue CAGR 5.1%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+5.7%+0.7%-8.2%-4.9%+20.4%+22.5%+1.6%+5.9%+5.9%+4.5%
Net income growth+408.3%-75.5%-19.4%-17.4%+42.7%-121.8%+371.3%-49.8%-38.2%
EPS growth+424.3%-75.0%-19.6%-16.7%+44.4%-122.0%+382.4%-50.0%-38.2%
Free cash flow growth-10.5%+63.5%-47.1%+30.5%+38.2%+52.7%-14.7%+27.0%-26.3%+21.5%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.